Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HKSE:01501's ROE % is ranked better than 79.2% of 798
companies
in the Medical Devices & Instruments industry
Industry Median: 2.51
vs HKSE:01501: 11.74
Shanghai INT Medical Instruments Co (HKSE:01501) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Shanghai INT Medical Instruments Co ROE % Related Terms
Shanghai INT Medical Instruments Co ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Shanghai INT Medical Instruments Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai INT Medical Instruments Co ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shanghai INT Medical Instruments Co's ROE % distribution charts can be found below:
* The bar in red indicates where Shanghai INT Medical Instruments Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Shanghai INT Medical Instruments Co (HKSE:01501) has a ROE % of 12.49% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Shanghai INT Medical Instruments Co and its competitors. This is near median its historical median of 11.75. Over the past decade, Shanghai INT Medical Instruments Co's ROE % has ranged from 9.50 to 27.19. According to the industry distribution chart, Shanghai INT Medical Instruments Co ranks #166 out of 798 companies in the Medical Devices & Instruments industry, placing it in the top 20.8%.
Is Shanghai INT Medical Instruments Co's ROE % too high?
Shanghai INT Medical Instruments Co's current ROE % of 12.49% is near median its 10-year median of 11.75. Over the past 10 years, this metric has ranged from a low of 9.50 to a high of 27.19. The Medical Devices & Instruments industry median ROE % is 2.51. Shanghai INT Medical Instruments Co's value of 12.49% is 397.6% above this industry median. Based on the distribution chart, Shanghai INT Medical Instruments Co ranks #166 out of 798 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai INT Medical Instruments Co has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai INT Medical Instruments Co's ROE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Shanghai INT Medical Instruments Co ranks #166 out of 798 companies for ROE %. This places Shanghai INT Medical Instruments Co in the top 21% of its industry — outperforming the majority of peers. The industry median ROE % is 2.51. Shanghai INT Medical Instruments Co's value of 12.49% is 397.6% above this benchmark. Historically, Shanghai INT Medical Instruments Co's own ROE % has ranged from 9.50 to 27.19 over the past decade. While the company's 10-year median is 11.75 vs. the industry median of 2.51, Shanghai INT Medical Instruments Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.51, based on 798 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai INT Medical Instruments Co's current ROE % of 12.49% is 397.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Shanghai INT Medical Instruments Co and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai INT Medical Instruments Co's current ROE % is 12.49%, which is near median its own 10-year median of 11.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai INT Medical Instruments Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai INT Medical Instruments Co (HKSE:01501) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$39.95, compared to a current price of HK$32.90 — trading 17.6% below its estimated fair value. The current ROE % is 12.49%, which is near median its 10-year median of 11.75 and 397.6% above the Medical Devices & Instruments industry median of 2.51. Shanghai INT Medical Instruments Co's overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Shanghai INT Medical Instruments Co (HKSE:01501), the current ROE % is 12.49% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai INT Medical Instruments Co (HKSE:01501) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai INT Medical Instruments Co stock appears to be undervalued.
The current stock price of HK$32.90 is trading 17.6% below its estimated GF Value™ of HK$39.95.
GuruFocus considers Shanghai INT Medical Instruments Co to be Modestly Undervalued.
Key valuation signals for HKSE:01501:
ROE %: 12.49% (near median its 10-year median of 11.75)
GF Value™: HK$39.95 vs. price of HK$32.90 (17.6% below fair value)
Industry Position: 397.6% above the Medical Devices & Instruments median (#166 of 798)
No single metric tells the full story. See the HKSE:01501 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai INT Medical Instruments Co Business Description
Shanghai INT Medical Instruments Co Ltd engages in the design and development of medical devices used in fields including peripheral intervention, neurological intervention, cardiovascular intervention, or implantation, and the design and development of equipment and moulds used for the production of medical devices. The company operates in the Chinese Mainland, Europe, the United States, and Other countries and regions. The majority of the revenue comes from the Chinese Mainland.
93GF Score
Get the complete analysis for HKSE:01501
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01501 has been successfully added to your 
